Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Symadex (C-1311) in Metastatic Colorectal Cancer After Oxaliplatin and/or Irinotecan Failure
2005-004258-28Phase 2Completed
- Sponsor
- Xanthus Pharmaceuticals, Inc.
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of C-1311 in metastatic colorectal adenocarcinoma (mCRC), sponsored by Xanthus Pharmaceuticals, Inc. Primary endpoint: Overall response rate (CR + PR). Started Dec 2005; status: completed.
02
Drugs
C-1311
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2005-004258-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004258-28.